For biopharma finance teams, clinical trial accruals take a lot of time. They are also prone to errors during the R&D close. Analysts spend days chasing CRO invoices. They manually reconcile spreadsheets and build accrual estimates. Those estimates are outdated the moment they are finished. At the end of the month, the team is exhausted and the numbers are still wrong.
The good news is this does not have to be the norm. Automating clinical trial accruals is now within reach for biopharma companies of all sizes — and the results are measurable. Teams that have made the shift report up to a 75% efficiency gain, a 60% faster close cycle, and forecast accuracy that exceeds 90%.
This guide explains what clinical trial accrual automation means. It explains why this challenge is especially difficult in biopharma R&D. It also shows how to approach it step by step. It explains what to look for in a purpose-built solution.
A clinical trial accrual is the process of recording R&D expenses in the correct accounting period. It applies even if invoices arrive later. Under GAAP and IFRS, biopharma companies must record costs as providers perform the services, not when providers bill them.
In practice, this means estimating how much work a CRO, clinical site, or other vendor finished by each period end. This applies even if no invoice has arrived. The accrual bridges the gap between operational progress and the general ledger.
Clinical trial accruals typically cover:
Each of these streams requires different data sources, different calculation logic, and different sign-off workflows. Across a portfolio of five or ten active trials, the complexity compounds quickly.
Most biopharma finance teams still use ERP systems (SAP, Oracle, NetSuite), Excel files, and email to manage clinical accruals. This approach creates four structural problems that no amount of spreadsheet optimization can solve.
Accruals calculated from delayed CRO invoices or month-end confirmations are always looking backward. By the time estimates are final, study activity may have shifted. Enrollment may speed up, a site may drop out, or a protocol amendment may change scope. The accrual goes stale before you post it.
Building an accrual model in Excel requires analysts to pull data from many systems. These can include EDC platforms, IRT systems, procurement tools, and contract management systems.
Analysts then copy the data into a workbook, apply formulas, and reconcile results with prior periods. Each handoff introduces the risk of error. Each formula cell is a potential failure point that auditors will want explained.
No single system connects operational trial progress to financial impact. Clinical operations teams track enrollment in one platform; finance tracks budget vs. actuals in another. When a change order is approved, the accrual model does not update automatically.
When a site is activated, the accrual model does not update automatically. Finance hears about it at month-end — if they hear about it at all.
Static accrual models assume the world stays constant between updates. In clinical development, it never does. Without dynamic, scenario-aware models, finance teams can't accurately project trial spend — and programs run over budget without warning.
"Condor is like night & day from our previous models." — Trishula Therapeutics
Before you can automate the process, it helps to understand what a well-designed accrual workflow actually looks like. The architecture has three distinct layers.
The inputs to any clinical accrual include:
In a manual process, analysts gather this data by hand. In an automated process, integrations pull this data continuously and map it to the right contract line items.
With the right data, the system uses calculation logic to create accrual estimates for every vendor and service line. This includes:
The outputs of the accrual process feed directly into the financial close. Specifically, the system produces:
This is also where the guided workflow lives. It includes checklists, role-based approvals, and audit trails. These features make the close defensible to Big 4 auditors.
The foundation of any accrual automation effort is a unified, structured repository of all your clinical contracts and amendments. This means contract value by service line, milestones, budget categories, and all approved change orders.
Without this foundation, automation is impossible — you can't calculate percent-complete against a contract you haven't structured. Start by extracting and standardizing your CRO agreements, CTAs, and ancillary vendor contracts.
Next, create a reliable link between your study work and the records in the general ledger. This requires SMART mapping logic. It translates key milestones, like a patient visit, a lab sample, or site activation. It maps them to matching contract line items and budget categories.
This mapping is where purpose-built clinical finance software creates the most value. Generic ERP systems and accrual tools were not built for the clinical R&D data model.
They need major custom setup, or manual workarounds, to meet these needs.
Once your contracts are structured and your mapping logic is in place, you need live data flowing into your accrual models. Integration points typically include:
Automated data ingestion eliminates the manual copy-paste that accounts for a significant portion of close cycle time — and the majority of accrual errors.
With structured data flowing in, the system can calculate accruals programmatically. Automated calculations should cover:
Automation here doesn't mean black-box algorithms. It means repeatable, auditable logic that finance teams can explain to auditors and sign off on confidently.
Automation handles the calculation. Workflow automation handles the coordination. A purpose-built clinical finance system should include:
This is where SOX compliance gets built in rather than bolted on. Teams working toward IPO readiness or operating under external audit scrutiny will find that structured workflows reduce the risk of audit findings tied to clinical R&D accruals.
"This [financial close] would never have been possible without Condor." — Intra-Cellular Therapies
The final step — and the one that transforms accruals from a compliance function into a strategic tool — is connecting accrual actuals to a forward-looking forecast. When your accrual data is clean, structured, and current, you can build scenario models that project trial spend under different enrollment, amendment, and timeline assumptions.
This closes the loop between the close process and FP&A, giving CFOs and VPs of Finance the real-time visibility they need to manage R&D budgets proactively.
Not all clinical finance tools are built the same. When evaluating solutions, look for these capabilities:
Generic ERP add-ons and industry-agnostic accrual tools (like Gappify or BlackLine) were not designed with biopharma R&D workflows in mind. A purpose-built platform should natively understand CRO contracts, CTAs, investigator fees, and protocol amendments — without requiring custom configuration to model these structures.
Look for native integrations with EDC platforms, IRT systems, ERP systems, and procurement tools. Manual data imports are a bottleneck and a source of error.
The system should automatically map operational data to contract line items, flag variances, and surface amendment-in-progress situations that require reconciliation before the close.
Every calculation, assumption change, and approval should be logged with user, timestamp, and rationale. This is non-negotiable for public companies and Series C+ stage companies preparing for audit.
The best systems give each function a role-specific dashboard built on the same underlying data model — so there's one version of the truth, not three.
The platform should allow finance teams to run "what if" models based on enrollment changes, protocol amendments, or timeline shifts — with the accrual layer feeding directly into the forecast.
The ROI on clinical accrual automation compounds quickly. Organizations that have implemented purpose-built automation report:
Beyond the numbers, there is a scaling benefit that spreadsheet-based processes simply cannot provide. One company scaled from 2 active trials to 10 in 120 days — without adding headcount — because their accrual process no longer required a dedicated analyst per study. Another team unlocked over $5M in clinical program savings in a single program through better vendor reconciliation and change order management.
For finance leaders, the business case is straightforward: manual accruals are a constraint on how fast the company can grow. Automation removes that constraint.
ERPs manage transactions. They were not built to calculate clinical trial accruals based on percent-complete methodologies and operational trial data. Most companies using SAP or Oracle for clinical accruals are doing the actual calculation in Excel and posting the result to the ERP. The automation opportunity is in the calculation layer, not the GL.
Manual processes work until they don't.
Inflection points often come sooner than teams expect. A new CFO might join. An IPO process might start.
A Series C audit might begin. A pipeline might expand. Building automation early is far less disruptive than adding it under pressure during a close or audit.
Purpose-built clinical finance platforms support fast implementations with minimal IT burden. The heavy lifting is in the clinical data model and integration layer. It comes pre-built, not from custom development.
Automating clinical trial accruals is not just an efficiency play. It is the foundation for transforming clinical finance from a reactive, backward-looking function into a proactive one.
Finance teams gain real-time visibility into trial spend. They also get accurate forecasts. They can scale as the pipeline grows.
Centralize your contract data. Link your key operational data sources. Move calculations out of spreadsheets and into a purpose-built system. The result is a faster close, cleaner audits, and a finance team that keeps up with complex biopharma R&D.
Condor is the Financial Cloud for Pharma R&D — purpose-built to automate clinical trial accruals, forecasting, budgeting, and benchmarking. To learn how leading biopharma finance teams are automating their R&D accruals with Condor, request a demo at condorsoftware.com.
